Přehled o publikaci
2023
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ, Jiří MAYER et. al.Basic information
Original name
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
Authors
KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ and Jiří MAYER
Edition
Bone Marrow Transplantation, LONDON, SPRINGERNATURE, 2023, 0268-3369
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
001171467900001
EID Scopus
2-s2.0-85168602322
Keywords in English
CMV infection; high-dose aciclovir
Links
LX22NPO5102, research and development project.
Changed: 9/3/2024 03:34, RNDr. Daniel Jakubík
Abstract
V originále
lt; 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir’s adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.
